Biodistribution of 213Bi–Metallothionein and 213Bi–IgG in Intact Mice
https://doi.org/10.56304/S2079562922030356
Abstract
The search of new approaches to development of radiopharmaceuticals based on antibodies and the retention of their specificity and affinity to antigens remains one of the most important problems of radiopharmaceutics. The metal-binding protein metallothionein has been proposed as a chelator for the α-emitting radionuclide 213Bi. In this work the results of biodistribution study of 213Bi−metallothionein (213Bi−MT), 213Bi−immunoglobulin (213Bi−IgG) and free 213Bi in a form of 213BiCl3 in intact mice are presented.
About the Authors
V М. Petriev
Tsyb Medical Radiological Research Centre – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
Russian Federation
Russian Federation
Kaluga oblast, Obninsk, 249031; Moscow, 115409
V. К. Tishchenko
Tsyb Medical Radiological Research Centre – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kaluga oblast, Obninsk, 249031
Р. V. Shegai
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kaluga oblast, Obninsk, 249036
S. А. Ivanov
Tsyb Medical Radiological Research Centre – Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kaluga oblast, Obninsk, 249031
А. D. Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Рeoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
Kaluga oblast, Obninsk, 249036; Moscow, 117198
References
1. Alenkorah S., Cassells I., Deroose C.M., et al. // Pharmaceutics. 2021. V. 13 (5) P. 599.
2. Nelson B.J.B., Andersson J.D., Wuest F. // Pharmaceutics. 2021. V. 13 (1). P. 49.
3. Listek M., Hönow A., Gossen M., et al. // Nat. Sci. Rep. 2020. V. 10. P. 1664.
4. Fichou N., Gouard S., Maurel C., et al. // Front. Med. 2015. V. 2. P. 76.
5. Fazel J., Rötzer S., Seidl C., et al. // Cancer Biol. Ther. 2015. V. 16. P. 1526.
6. Jurcic J.G., Larson S.M., Sgouros G., et al. // Blood. 2002. V. 100. P. 1233.
7. Allen B.J., Singla A.A., Rizvi S.M.A., et al. // Immunotherapy. 2011. V. 3. P. 1041.
8. Raja C., Graham P., Abbas Rizvi S.M., et al. // Cancer Biol. Ther. 2007. V. 6. P. 846.
9. Autenrieth M.E., Seidl C., Bruchertseifer F., et al. // Eur. J. Nucl. Med. Mol. Imaging. 2018. V. 45. P. 1364.
10. Si M., Lang J. // J. Hematol. Oncol. 2018. V. 11 (1). P. 107.
11. Petriev V.M., Skvortsov V.G., Novikova I.S., et al. // Vopr. Biol. Med. Pharm. Khim. 2009. No. 6. P. 46 (in Russian).
Review
For citations:
Petriev V.М., Tishchenko V.К., Shegai Р.V., Ivanov S.А., Kaprin А.D. Biodistribution of 213Bi–Metallothionein and 213Bi–IgG in Intact Mice. Nuclear Physics and Engineering. 2022;13(5):510-514. (In Russ.) https://doi.org/10.56304/S2079562922030356
Views:
19
Email this article 